Amplification and Overexpression of c-met Gene in Epstein-Barr Virus-Associated Gastric Carcinomas (original) (raw)
Article navigation
Research Articles| January 24 2002
aFirst Department of Surgery,
bDivision of Persistent and Oncogenic viruses, Center for Chronic Viral Diseases, and
Search for other works by this author on:
aFirst Department of Surgery,
Search for other works by this author on:
aFirst Department of Surgery,
Search for other works by this author on:
dDepartment of Pathology, Kagoshima Medical Laboratory Center, Kagoshima, Japan
Search for other works by this author on:
cDepartment of Public Health, Faculty of Medicine, Kagoshima University, Kagoshima,
Search for other works by this author on:
bDivision of Persistent and Oncogenic viruses, Center for Chronic Viral Diseases, and
Search for other works by this author on:
cDepartment of Public Health, Faculty of Medicine, Kagoshima University, Kagoshima,
Search for other works by this author on:
aFirst Department of Surgery,
Search for other works by this author on:
Oncology (2002) 62 (1): 60–65.
Abstract
To reveal the role of oncogenes in Epstein-Barr virus (EBV)-positive gastric carcinomas, the amplification and overexpression of the c-met gene were examined by a competitive polymerase chain reaction and immunohistochemistry, respectively. The proportion of c-met amplification and overexpression in EBV-positive and -negative carcinomas did not differ significantly. The amplification and overexpression of the c-met gene in EBV-negative gastric carcinomas were significantly associated with upper location, deeper invasion and lymphatic invasion, while in EBV-positive gastric carcinomas a significant correlation with c-met activation was observed only in deeper invasion. However, none of the observed associations of c-met amplification or overexpression with clinicopathological features in the EBV-positive and -negative carcinomas differed significantly in their strength or direction. These results suggest that the amplification and overexpression of c-met gene do not play a different role in the progression and metastasis of EBV-positive and EBV-negative gastric carcinomas.
References
Shibata D, Weiss LM: Epstein-Barr virus-associated gastric adenocarcinoma. Am J Pathol 1992;140:769–774.
Tokunaga M, Land CE, Uemura Y, Tokudome T, Tanaka S, Sato E: Epstein-Barr virus in gastric carcinoma. Am J Pathol 1993;143:1250–1254.
Imai S, Koizumi S, Sugiura M, Tokunaga M, Uemura Y, Yamamoto N, Tanaka S, Sato E, Osato T: Gastric carcinoma: Monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci USA 1994;91:9131–9135.
Tahara E: Genetic alterations in human gastrointestinal cancers. Cancer 1995;75:1410–1417.
Chong JM, Fukayama M, Hayashi Y, Takizawa T, Koike M, Konishi M, Kikuchi-Yanoshita R, Miyaki M: Microsatellite instability in the progression of gastric carcinoma. Cancer Res 1994;54:4595–4597.
Cooper CS, Morag P, Blair DG, Tainsky MA, Huebner K, Croce CM, Woude GFV: Molecular cloning of a few transforming gene from a chemically transformed human cell line. Nature 1984;311:29–33.
Zarnegar R, Muga S, Enghild J, Michalopoulos G: NH2-terminal amino acid sequence of rabbit hepatopoietin A, a heparin-binding polypeptide growth factor for hepatocyte. Biochem Biophys Res Commun 1989;163:1370–1376.
Miyazawa J, Tsubouchi H, Naka D, Takahashi K, Okigaki M, Arakaki N, Nakayama H, Hirono S, Sakiyama O, Takahashi K, Gohda E, Daikuhara Y, Kitamura N: Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. Biochem Biophys Res Commun 1989;163:967–973.
Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugiura A, Tashiro K, Shimizu S: Molecular cloning and expression of human hepatocyte growth factor. Nature 1989;342:440–443.
Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, Tahara E: Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 1992;189:227–232.
Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, Matsuda M, Sakaguchi T, Hirao T, Nakano H: The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999;85:1894–1902.
Japanese Gastric Cancer Association: Japanese classification of gastric carcinoma, ed 2, English. Gastric Cancer 1998;1:10–24.
Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT, Day ML: Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995;147:386–396.
Jung W, Gastren E, Odenthal M, Vande WGF, Ishii T, Dienes HP, Pindholm D, Shirmacher P: Expression and functional interaction of hepatocyte growth factor-scatter factor and its receptor c-met in mammalian brain. J Cell Biol 1994;126:485–494.
Di Renzo MF, Olivero M, Ferro S, Prat M, Bongarzone I, Pilotti S, Belfiore A, Costantino A, Vigneri R, Pierotti MA, Comoglio PM: Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene 1992;7:2549–2553.
Di Renzo MF, Narsimhan RP, Olivero M, Bretti S, Giordano S, Medico E, Gaglia P, Zara P, Comoglio PM: Expression of the Met HGF receptor in normal and neoplastic human tissues. Oncogene 1991;6:1997–2003.
Tannapfel A, Yasui W, Yokozaki H, Wittekind C, Tahara E: Effect of hepatocyte growth factor on the expression of E- and P-cadherin in gastric carcinoma cell lines. Virchows Arch 1994;425:139–144.
Wagatsuma S, Konno R, Sato S, Yajima K: Tumor angiogenesis, hepatocyte growth factor, and c-met expression in endometrial carcinoma. Cancer 1998;82:520–530.
Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, Tahara E: Aberrant expression of c-met mRNA in human gastric carcinomas. Int J Cancer 1993;55:72–75.
Watanabe H, Enjoji M, Imai T: Gastric carcinoma with lymphoid stroma. Its morphologic characteristics and prognostic correlations. Cancer 1976;38:232–243.
Tokunaga M, Land CE: Epstein-Barr virus involvement in gastric cancer: Biomarker for lymph node metastasis. Cancer Epidemiol Biomarkers Prev 1998;7:449–450.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
Sign in
Digital Version
Pay-Per-View Access
$39.00
1 Karger Article Bundle Token
$150
Rental
This article is also available for rental through DeepDyve. 